CN107567454B - 用于治疗cns障碍的稠合二氢-4h-吡唑并[5,1-c][1,4]噁嗪基化合物及其类似物 - Google Patents

用于治疗cns障碍的稠合二氢-4h-吡唑并[5,1-c][1,4]噁嗪基化合物及其类似物 Download PDF

Info

Publication number
CN107567454B
CN107567454B CN201680018684.5A CN201680018684A CN107567454B CN 107567454 B CN107567454 B CN 107567454B CN 201680018684 A CN201680018684 A CN 201680018684A CN 107567454 B CN107567454 B CN 107567454B
Authority
CN
China
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
formula
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680018684.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN107567454A (zh
Inventor
米兰·奇蒂尔
肖恩·恩格尔
泰琳·G·阿纳尼亚
瓦迪姆·亚历山德罗夫
艾默尔·莱希
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pgi Drug Development Corp
Sunovion Pharmaceuticals Inc
Original Assignee
Pgi Drug Development Corp
Sunovion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pgi Drug Development Corp, Sunovion Pharmaceuticals Inc filed Critical Pgi Drug Development Corp
Priority to CN202010051639.8A priority Critical patent/CN111171047B/zh
Publication of CN107567454A publication Critical patent/CN107567454A/zh
Application granted granted Critical
Publication of CN107567454B publication Critical patent/CN107567454B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Addiction (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN201680018684.5A 2015-02-11 2016-02-11 用于治疗cns障碍的稠合二氢-4h-吡唑并[5,1-c][1,4]噁嗪基化合物及其类似物 Active CN107567454B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010051639.8A CN111171047B (zh) 2015-02-11 2016-02-11 用于治疗cns障碍的稠合二氢-4h-吡唑并[5,1-c][1,4]噁嗪基化合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562115043P 2015-02-11 2015-02-11
US62/115,043 2015-02-11
PCT/US2016/017527 WO2016130790A1 (en) 2015-02-11 2016-02-11 Fused dihydro-4h-pyrazolo[5,1-c][1,4]oxazinyl compounds and analogs for treating cns disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202010051639.8A Division CN111171047B (zh) 2015-02-11 2016-02-11 用于治疗cns障碍的稠合二氢-4h-吡唑并[5,1-c][1,4]噁嗪基化合物

Publications (2)

Publication Number Publication Date
CN107567454A CN107567454A (zh) 2018-01-09
CN107567454B true CN107567454B (zh) 2020-02-18

Family

ID=55456906

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202010051639.8A Active CN111171047B (zh) 2015-02-11 2016-02-11 用于治疗cns障碍的稠合二氢-4h-吡唑并[5,1-c][1,4]噁嗪基化合物
CN201680018684.5A Active CN107567454B (zh) 2015-02-11 2016-02-11 用于治疗cns障碍的稠合二氢-4h-吡唑并[5,1-c][1,4]噁嗪基化合物及其类似物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202010051639.8A Active CN111171047B (zh) 2015-02-11 2016-02-11 用于治疗cns障碍的稠合二氢-4h-吡唑并[5,1-c][1,4]噁嗪基化合物

Country Status (21)

Country Link
US (4) US9758529B2 (enExample)
EP (3) EP4006039B1 (enExample)
JP (4) JP6561128B2 (enExample)
KR (1) KR102623321B1 (enExample)
CN (2) CN111171047B (enExample)
AU (4) AU2016219247B2 (enExample)
BR (1) BR112017017349B1 (enExample)
CA (1) CA2976092A1 (enExample)
DK (1) DK3256476T3 (enExample)
EA (1) EA201791802A1 (enExample)
ES (1) ES2712627T3 (enExample)
IL (2) IL253907B (enExample)
MX (1) MX371197B (enExample)
NZ (1) NZ734972A (enExample)
PH (1) PH12017501423A1 (enExample)
PL (1) PL3256476T3 (enExample)
PT (1) PT3256476T (enExample)
SG (1) SG11201706516WA (enExample)
UA (1) UA123262C2 (enExample)
WO (1) WO2016130790A1 (enExample)
ZA (1) ZA201706074B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3256476T3 (pl) * 2015-02-11 2019-05-31 Pgi Drug Discovery Llc Związki i analogi fuzyjnego dihydro-4h-pirazolo[5,1-c][1,4]oksazynylu w leczeniu zaburzeń oun
CA3032302A1 (en) 2016-07-29 2018-02-01 Taleen G. Hanania Compounds and compositions and uses thereof
CN110087687A (zh) 2016-07-29 2019-08-02 赛诺维信制药公司 化合物、组合物及其用途
KR101753092B1 (ko) 2016-12-14 2017-07-04 성일하이텍(주) 리튬 함유 폐액으로부터 인산리튬 제조방법
US10850989B2 (en) 2016-12-20 2020-12-01 Sungeel Hitech Co., Ltd. Method for preparing solid lithium salt from lithium solution
EP3645120B1 (en) 2017-06-30 2024-12-11 Chase Therapeutics Corporation Nk-1 antagonist compositions and methods for use in treating depression
CN111183138A (zh) 2017-08-02 2020-05-19 赛诺维信制药公司 异色满化合物以及用途
WO2019236808A1 (en) 2018-06-07 2019-12-12 Sunovion Pharmaceuticals Inc. Salts of a oxazino[4,3-b]indazole derivative and crystalline forms, processes for preparing, therapeutic uses, and pharmaceutical compositions thereof
WO2020087031A1 (en) 2018-10-26 2020-04-30 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
MX2021010880A (es) 2019-03-14 2022-01-18 Sunovion Pharmaceuticals Inc Sales de un compuesto de isocromanilo y formas cristalinas, procesos de preparacion, usos terapeuticos y composiciones farmaceuticas de las mismas.
TW202237622A (zh) 2020-12-04 2022-10-01 美商蘇諾維恩藥業公司 雜環化合物的鹽及其晶型、製備方法、治療用途與醫藥組合物
WO2022217233A1 (en) * 2021-04-08 2022-10-13 Sunovion Pharmaceuticals Inc. Fused dihydro-4h-pyrazolo[5,1-c][1,4]oxazinyl compounds and analogs for treating cns disorders
EP4416133A1 (en) * 2021-10-11 2024-08-21 Baylor College of Medicine G-protein-coupled receptor regulators and methods of use thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007120594A1 (en) * 2006-04-12 2007-10-25 Wyeth Substituted-dihydro[1,4]oxazino[2,3,4-hi]indazole derivatives as 5-hydroxytryptamine-6 ligands
WO2013067248A1 (en) * 2011-11-04 2013-05-10 Vertex Pharmaceuticals Incorporated Benzoxazines as modulators of ion channels
WO2013192346A1 (en) * 2012-06-20 2013-12-27 Vanderbilt University Substituted bicyclic alkoxy pyrazole analogs as allosteric modulators of mglur5 receptors
JP2014214130A (ja) * 2013-04-26 2014-11-17 大正製薬株式会社 ジヒドロイミダゾオキサゾール誘導体を含有する医薬

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3995052A (en) * 1973-07-09 1976-11-30 Ayerst Mckenna And Harrison Ltd. Indenopyran- and indenothiopyranalkylamines III in the treatment of depression
US4041169A (en) * 1975-03-05 1977-08-09 Ayerst Mckenna And Harrison Ltd. Pharmaceutical method for using pyrano-and thiopyranoindole derivatives
SG173639A1 (en) * 2009-02-11 2011-09-29 Sunovion Pharmaceuticals Inc Histamine h3 inverse agonists and antagonists and methods of use thereof
SG10201401661RA (en) * 2009-12-04 2014-07-30 Sunovion Pharmaceuticals Inc Multicycle compounds and pharmaceutical compositions useful for the treatment of neurological disorders
KR20140099556A (ko) * 2010-12-16 2014-08-12 에프. 호프만-라 로슈 아게 트라이사이클릭 pi3k 억제제 화합물 및 이의 사용 방법
KR20140082765A (ko) * 2011-10-05 2014-07-02 에프. 호프만-라 로슈 아게 V1a 길항제로서의 사이클로헥실-4H,6H-5-옥사-2,3,10b-트라이아자-벤조[e]아줄렌
EP2794608B1 (en) * 2011-12-22 2016-09-14 Merck Patent GmbH Tetraaza-cyclopenta[a]indenyl and their use as positive allosteric modulators
PL3256476T3 (pl) * 2015-02-11 2019-05-31 Pgi Drug Discovery Llc Związki i analogi fuzyjnego dihydro-4h-pirazolo[5,1-c][1,4]oksazynylu w leczeniu zaburzeń oun
DK3256466T3 (da) * 2015-02-11 2022-05-02 Sunovion Pharmaceuticals Inc 1-heterocyclyl-isochromanylforbindelser og analoger til behandling af cns-forstyrrelser

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007120594A1 (en) * 2006-04-12 2007-10-25 Wyeth Substituted-dihydro[1,4]oxazino[2,3,4-hi]indazole derivatives as 5-hydroxytryptamine-6 ligands
WO2013067248A1 (en) * 2011-11-04 2013-05-10 Vertex Pharmaceuticals Incorporated Benzoxazines as modulators of ion channels
WO2013192346A1 (en) * 2012-06-20 2013-12-27 Vanderbilt University Substituted bicyclic alkoxy pyrazole analogs as allosteric modulators of mglur5 receptors
JP2014214130A (ja) * 2013-04-26 2014-11-17 大正製薬株式会社 ジヒドロイミダゾオキサゾール誘導体を含有する医薬

Also Published As

Publication number Publication date
AU2016219247B2 (en) 2020-08-13
EP4006039A1 (en) 2022-06-01
AU2020267209A1 (en) 2020-12-10
BR112017017349A2 (en) 2018-04-10
US20210300942A1 (en) 2021-09-30
WO2016130790A1 (en) 2016-08-18
CN111171047A (zh) 2020-05-19
EP4006039B1 (en) 2024-01-10
US20200024286A1 (en) 2020-01-23
PH12017501423A1 (en) 2018-03-19
CN107567454A (zh) 2018-01-09
PT3256476T (pt) 2019-03-01
MX371197B (es) 2020-01-22
CN111171047B (zh) 2023-06-23
IL253907A0 (en) 2017-10-31
EA201791802A1 (ru) 2018-02-28
DK3256476T3 (en) 2019-03-11
KR102623321B1 (ko) 2024-01-09
JP6561128B2 (ja) 2019-08-14
BR112017017349B1 (pt) 2024-01-23
JP2023036611A (ja) 2023-03-14
CA2976092A1 (en) 2016-08-18
AU2024204310A1 (en) 2024-07-11
ES2712627T3 (es) 2019-05-14
IL253907B (en) 2020-09-30
AU2016219247A1 (en) 2017-09-21
UA123262C2 (uk) 2021-03-10
PL3256476T3 (pl) 2019-05-31
JP6928629B2 (ja) 2021-09-01
ZA201706074B (en) 2023-05-31
US20160264597A1 (en) 2016-09-15
IL277658A (en) 2020-11-30
JP2021183624A (ja) 2021-12-02
JP2018505204A (ja) 2018-02-22
EP3256476B1 (en) 2019-01-23
EP3256476A1 (en) 2017-12-20
MX2017010362A (es) 2018-05-04
AU2022259828A1 (en) 2022-12-01
NZ734972A (en) 2023-07-28
SG11201706516WA (en) 2017-09-28
US20180057506A1 (en) 2018-03-01
JP2019196385A (ja) 2019-11-14
US9758529B2 (en) 2017-09-12
KR20170129729A (ko) 2017-11-27
IL277658B (en) 2022-03-01
EP3539967A1 (en) 2019-09-18

Similar Documents

Publication Publication Date Title
CN107567454B (zh) 用于治疗cns障碍的稠合二氢-4h-吡唑并[5,1-c][1,4]噁嗪基化合物及其类似物
CN104725359B (zh) 取代的哌嗪化合物及其使用方法和用途
CN112601752A (zh) Map4k1的新颖抑制剂
CN102388043A (zh) 组胺h3反相激动剂和拮抗剂及其使用方法
CN107531674B (zh) 用于治疗cns障碍的1-杂环基异苯并二氢吡喃基化合物和类似物
CN109476628B (zh) 作为trpa1调节剂的磺酰基环烷基酰胺化合物
CN111183138A (zh) 异色满化合物以及用途
CN117177974A (zh) 含咪唑稠环类衍生物、其制备方法及其在医药上的应用
CN104364253A (zh) 作为kat ii抑制剂的三环化合物
HK40073618A (en) Fused dihydro-4h-pyrazolo[5,1-c][1,4]oxazinyl compounds and analogs for treating cns disorders
HK40006461A (en) Process for the preparation of fused dihydro-4h-pyrazolo[5,1-c][1,4]oxazinyl compounds
HK1241875B (en) Fused dihydro-4h-pyrazolo[5,1-c][1,4]oxazinyl compounds and analogs for treating cns disorders
HK1241875A1 (en) Fused dihydro-4h-pyrazolo[5,1-c][1,4]oxazinyl compounds and analogs for treating cns disorders
HK40073618B (en) Fused dihydro-4h-pyrazolo[5,1-c][1,4]oxazinyl compounds and analogs for treating cns disorders

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant